

Markku S Nieminen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4216611/publications.pdf>

Version: 2024-02-01

75
papers

10,832
citations

117625

34
h-index

71685

76
g-index

77
all docs

77
docs citations

77
times ranked

19043
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of sudden cardiac death associated with QRS, QTc, and JTc intervals in the general population. <i>Heart Rhythm</i> , 2022, 19, 1297-1303.	0.7	10
2	Poor adherence to beta-blockers is associated with increased long-term mortality even beyond the first year after an acute coronary syndrome event. <i>Annals of Medicine</i> , 2020, 52, 74-84.	3.8	7
3	Prognostic impact of angiographic findings, procedural success, and timing of percutaneous coronary intervention in cardiogenic shock. <i>ESC Heart Failure</i> , 2020, 7, 768-773.	3.1	4
4	Genetic basis and outcome in a nationwide study of Finnish patients with hypertrophic cardiomyopathy. <i>ESC Heart Failure</i> , 2019, 6, 436-445.	3.1	26
5	Prognostic impact of baseline and residual SYNTAX scores in cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1-8.	1.7	11
6	Smoking confounds the periodontal diagnostics using saliva biomarkers. <i>Journal of Periodontology</i> , 2019, 90, 475-483.	3.4	11
7	ECG left ventricular hypertrophy as a risk predictor of sudden cardiac death. <i>International Journal of Cardiology</i> , 2019, 276, 125-129.	1.7	36
8	Electrocardiographic predictors of atrial fibrillation in nonhypertensive and hypertensive individuals. <i>Journal of Hypertension</i> , 2018, 36, 1874-1881.	0.5	17
9	<i>Aggregatibacter actinomycetemcomitans</i> serotypes associate with periodontal and coronary artery disease status. <i>Journal of Clinical Periodontology</i> , 2018, 45, 413-421.	4.9	23
10	Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2018, 20, 1081-1099.	7.1	57
11	Relation of Use of Red Blood Cell Transfusion After Acute Coronary Syndrome to Long-Term Mortality. <i>American Journal of Cardiology</i> , 2018, 121, 1496-1504.	1.6	3
12	Altered mental status predicts mortality in cardiogenic shock – results from the CardShock study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 38-44.	1.0	26
13	Immunologic burden links periodontitis to acute coronary syndrome. <i>Atherosclerosis</i> , 2018, 268, 177-184.	0.8	56
14	Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. <i>Scientific Reports</i> , 2018, 8, 14200.	3.3	28
15	Salivary biomarkers in association with periodontal parameters and the periodontitis risk haplotype. <i>Innate Immunity</i> , 2018, 24, 439-447.	2.4	11
16	Saliva and serum biomarkers in periodontitis and coronary artery disease. <i>Journal of Clinical Periodontology</i> , 2018, 45, 1045-1055.	4.9	31
17	Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. <i>European Heart Journal</i> , 2018, 39, 2562-2573.	2.2	126
18	Predictive value of the baseline electrocardiogram ST-segment pattern in cardiogenic shock: Results from the CardShock Study. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12561.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	11.4	84
20	Lipopolysaccharide, a possible molecular mediator between periodontitis and coronary artery disease. <i>Journal of Clinical Periodontology</i> , 2017, 44, 784-792.	4.9	56
21	Incidence rates, correlates, and prognosis of electrocardiographic P-wave abnormalities – a nationwide population-based study. <i>Journal of Electrocardiology</i> , 2017, 50, 925-932.	0.9	23
22	The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock – Results from the CardShock Study. <i>International Journal of Cardiology</i> , 2017, 226, 48-52.	1.7	38
23	The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure. <i>European Heart Journal Supplements</i> , 2017, 19, C15-C21.	0.1	7
24	Genetic Variants Contributing to Circulating Matrix Metalloproteinase 8 Levels and Their Association With Cardiovascular Diseases. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	21
25	Genetic Risk Scores Predict Recurrence of Acute Coronary Syndrome. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 172-178.	5.1	21
26	The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. <i>International Journal of Cardiology</i> , 2016, 218, 150-157.	1.7	60
27	Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. <i>International Journal of Cardiology</i> , 2016, 215, 26-31.	1.7	12
28	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. <i>European Heart Journal</i> , 2016, 37, 1967-1976.	2.2	433
29	Left ventricular mechanical dispersion is associated with nonsustained ventricular tachycardia in hypertrophic cardiomyopathy. <i>Annals of Medicine</i> , 2016, 48, 417-427.	3.8	19
30	Prediction of sudden cardiac death with automated high-throughput analysis of heterogeneity in standard resting 12-lead electrocardiograms. <i>Heart Rhythm</i> , 2016, 13, 713-720.	0.7	46
31	Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis. <i>International Journal of Cardiology</i> , 2016, 202, 138-143.	1.7	58
32	Assessment of Myocardial Infarct Size with Body Surface Potential Mapping: Validation against Contrast-Enhanced Cardiac Magnetic Resonance Imaging. <i>Annals of Noninvasive Electrocardiology</i> , 2015, 20, 240-252.	1.1	2
33	Quantitative PCR analysis of salivary pathogen burden in periodontitis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2015, 5, 69.	3.9	40
34	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. <i>PLoS Genetics</i> , 2015, 11, e1005378.	3.5	331
35	The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy. <i>PLoS ONE</i> , 2015, 10, e0134184.	2.5	18
36	Genetic Variants on Chromosome 1p13.3 Are Associated with Non-ST Elevation Myocardial Infarction and the Expression of DRAM2 in the Finnish Population. <i>PLoS ONE</i> , 2015, 10, e0140576.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Ectopic Fat Depots and Left Ventricular Function in Nondiabetic Men With Nonalcoholic Fatty Liver Disease. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	2.6	83
38	The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. <i>International Journal of Cardiology</i> , 2015, 191, 256-264.	1.7	125
39	Directional dominance on stature and cognition in diverse human populations. <i>Nature</i> , 2015, 523, 459-462.	27.8	173
40	Left Ventricular Wall Stress—Mass—Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients. <i>Hypertension</i> , 2015, 66, 945-953.	2.7	20
41	A comprehensive 1000 Genomes—based genome-wide association meta-analysis of coronary artery disease. <i>Nature Genetics</i> , 2015, 47, 1121-1130.	21.4	2,054
42	Coagulation changes in takotsubo cardiomyopathy support acute phase reaction and catecholamine excess, but not thrombus production. <i>International Journal of Cardiology</i> , 2014, 177, 1063-1065.	1.7	7
43	Cardiac steatosis in patients with dilated cardiomyopathy. <i>Heart</i> , 2014, 100, 1107-1112.	2.9	28
44	Low-Expression Variant of Fatty Acid—Binding Protein 4 Favors Reduced Manifestations of Atherosclerotic Disease and Increased Plaque Stability. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 588-598.	5.1	28
45	Acute Heart Failure With and Without Concomitant Acute Coronary Syndromes: Patient Characteristics, Management, and Survival. <i>Journal of Cardiac Failure</i> , 2014, 20, 723-730.	1.7	29
46	Differences in ST-elevation and T-wave amplitudes do not reliably differentiate takotsubo cardiomyopathy from acute anterior myocardial infarction. <i>Journal of Electrocardiology</i> , 2014, 47, 692-699.	0.9	36
47	Circulating cell-free DNA is associated with cardiometabolic risk factors: The Health 2000 Survey. <i>Atherosclerosis</i> , 2014, 233, 268-271.	0.8	49
48	Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. <i>Nature Genetics</i> , 2013, 45, 501-512.	21.4	578
49	Subgingival <i>Aggregatibacter actinomycetemcomitans</i> associates with the risk of coronary artery disease. <i>Journal of Clinical Periodontology</i> , 2013, 40, 583-590.	4.9	23
50	Cohort Profile: The Corogene study. <i>International Journal of Epidemiology</i> , 2012, 41, 1265-1271.	1.9	55
51	A common periodontal pathogen has an adverse association with both acute and stable coronary artery disease. <i>Atherosclerosis</i> , 2012, 223, 478-484.	0.8	69
52	Periodontitis is associated with angiographically verified coronary artery disease. <i>Journal of Clinical Periodontology</i> , 2011, 38, 1007-1014.	4.9	72
53	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. <i>Nature Genetics</i> , 2010, 42, 937-948.	21.4	2,634
54	Effects of Levosimendan on the Energy Balance: Preclinical and Clinical Evidence. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 302-310.	1.9	40

#	ARTICLE	IF	CITATIONS
55	Oral levosimendan in patients with severe chronic heart failure – The PERSIST study. <i>European Journal of Heart Failure</i> , 2008, 10, 1246-1254.	7.1	44
56	Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. <i>European Journal of Heart Failure</i> , 2008, 10, 140-148.	7.1	134
57	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. <i>European Heart Journal</i> , 2006, 27, 2725-2736.	2.2	1,063
58	Definition and Epidemiology of Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 5-10.	1.6	113
59	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. <i>European Heart Journal</i> , 2005, 26, 384-416.	2.2	1,114
60	Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial. <i>American Journal of Hypertension</i> , 2002, 15, A15.	2.0	5
61	Does losartan treated patients with albuminuria have better cardiovascular outcome than those treated with atenolol? The LIFE study. <i>American Journal of Hypertension</i> , 2002, 15, A21.	2.0	0
62	Echocardiographic Left Ventricular Geometry in Hypertensive Patients with Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study. <i>Blood Pressure</i> , 2001, 10, 74-82.	1.5	105
63	Late Fields of the Magnetocardiographic QRS Complex as Indicators of Propensity to Sustained Ventricular Tachycardia after Myocardial Infarction. <i>Journal of Cardiovascular Electrophysiology</i> , 2000, 11, 413-420.	1.7	39
64	Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 661-665.	2.4	20
65	Effects of acute alcohol infusion on duration and dispersion of QT interval in male patients with coronary artery disease and in healthy controls. <i>Clinical Cardiology</i> , 1999, 22, 591-594.	1.8	51
66	Pharmacology of Levosimendan: A New Myofilament Calcium Sensitizer. <i>Cardiovascular Drug Reviews</i> , 1996, 14, 286-316.	4.1	22
67	Profuse Mediastinal Haemorrhage Due to Mediastinitis after Sternotomy: Report of Three Cases and Review of the Literature. <i>Scandinavian Journal of Thoracic and Cardiovascular Surgery</i> , 1996, 30, 167-173.	0.2	10
68	Can High Frequency Ultrasound and MRI Diagnose Malignant Atheromatous Plaque In Vitro?.. <i>International Heart Journal</i> , 1995, 36, 235-245.	0.6	1
69	Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. <i>International Journal of Cardiovascular Imaging</i> , 1994, 10, 243-252.	0.6	21
70	Hemodynamic effects of the novel cardiotonic drug simendan: Echocardiographic assessment in healthy volunteers. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 263-269.	2.6	7
71	Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 554-563.	4.7	24
72	Cytomegalovirus infection accelerates cardiac allograft vasculopathy: correlation between angiographic and endomyocardial biopsy findings in heart transplant patients. <i>Transplant International</i> , 1993, 6, 341-347.	1.6	20

#	ARTICLE	IF	CITATIONS
73	Haemodynamic Effects of Bopindolol and Atenolol in Coronary Artery Disease A Noninvasive Study. <i>Annals of Medicine</i> , 1990, 22, 221-224.	3.8	1
74	Acute Cardiovascular Effects of Intravenous Cimetidine. <i>Acta Medica Scandinavica</i> , 1985, 217, 277-280.	0.0	20
75	Etiology of Mild Acute Infectious Myocarditis. <i>Acta Medica Scandinavica</i> , 1983, 213, 65-73.	0.0	92